Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma - PressReach
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Roche launches VENTANA BAP1 assay globally to support mesothelioma diagnosis
Automated immunohistochemistry test helps differentiate malignancies and preserve limited patient tissue for further analysis IN BRIEFKEY TAKEAWAYSFAQs Roche has announced the worldwide launch of the VENTANA BAP1 (SP527) assay, an automated immunohistochemistry test designed to help pathologists identify malignant mesothelioma … Read the full press release →
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma - PressReach
The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen. Most patients are diagnosed with mesothelioma late, resulting in a median overall survival of just 12 to 18 months.1 Roche's comprehensive cancer diagnostic portfolio delivers end-to-end clinical answers … Continue reading "Roche strengthens cancer diagnostic portfolio …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
